The dynamics in the market are changing. And Cramer says investors need to change, accordingly.» Read More
*Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.
*Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.
*Best Buy tumbles after results, DSW higher. *Digital Ally gains again, has tripled this month. "People aren't going to do anything too aggressive until there's some kind of catalyst, either positive or negative, and we may end up consolidating around 2,000 for a while," said Michael O'Rourke, chief market strategist at JonesTrading in Greenwich, Connecticut.
Biotechs rallied after Roche Holding AG agreed to buy InterMune Inc for $8.3 billion in cash, the latest vote of confidence in a sector that many, including Federal Reserve Chair Janet Yellen, are worried is overvalued. InterMune jumped 36 percent to $73.00, with the Nasdaq Biotech index up 2.4 percent.
Some of Tuesday's midday movers:
Aug 5- Regeneron Pharmaceuticals Inc on Tuesday reported higher-than-expected quarterly revenue and earnings on surging demand for its Eylea treatment for macular degeneration, and stuck to its full-year sales forecast for the drug.
Cramer likes to review the S&P 500’s Daily Action Charts in an effort to find stocks that could work higher.
Some of Wednesday's midday movers:
*Twitter rallies after blockbuster results. NEW YORK, July 30- U.S. stocks were flat on Wednesday, paring earlier gains as a strong read on second-quarter economic growth sparked concerns the Federal Reserve may adjust its stimulus earlier than expected.
*Twitter rallies after blockbuster results. *Biotechs rally on Amgen results, Regeneron trial data. Twitter Inc surged on heavy volume, jumping 25 percent to $48.25 in its biggest one-day advance ever after reporting that monthly active users had risen a better-than-expected 24 percent in the second quarter.
CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.
Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.
If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.
Some of the names on the move ahead of the open.
If the charts are to be believed, the path of least resistance for these 4 stocks should be higher.
Some of Thursday's midday movers:
Cramer says the price action in Tuesday’s market is sending an important message about what to buy in the days ahead.
Some of Friday's midday movers:
For the past several months biotech stocks have fallen out of favor on Wall Street. That may be about to change.
Valeant's New York- listed shares dropped 1 percent by midday to $128.66, paring earlier losses, while Allergan stock lost 4.1 percent to $158.29. Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30.